Enzo Biochem, Inc. (ENZB)
OTCMKTS
· Delayed Price · Currency is USD
0.6705
-0.0050 (-0.74%)
At close: Jun 27, 2025
Enzo Biochem Revenue
Enzo Biochem had revenue of $6.40M in the quarter ending April 30, 2025, a decrease of -20.19%. This brings the company's revenue in the last twelve months to $27.47M, down -17.59% year-over-year. In the fiscal year ending July 31, 2024, Enzo Biochem had annual revenue of $31.91M with 2.72% growth.
Revenue (ttm)
27.47M
Revenue Growth
-17.59%
P/S Ratio
1.03
Revenue / Employee
209.73K
Employees
136
Market Cap
28.29M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jul 31, 2024 | 31.91M | 846.00K | 2.72% |
Jul 31, 2023 | 31.06M | -1.58M | -4.85% |
Jul 31, 2022 | 32.64M | -85.09M | -72.27% |
Jul 31, 2021 | 117.73M | 41.71M | 54.87% |
Jul 31, 2020 | 76.02M | -5.15M | -6.34% |
Jul 31, 2019 | Pro | Pro | Pro |
Jul 31, 2018 | Pro | Pro | Pro |
Jul 31, 2017 | Pro | Pro | Pro |
Jul 31, 2016 | Pro | Pro | Pro |
Jul 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Elite Pharmaceuticals | 70.00M |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
American Oncology Network | 1.76B |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
Enzo Biochem News
- 1 day ago - ENZO BIOCHEM INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enzo Biochem, Inc. - ENZB - Business Wire
- 3 days ago - ENZB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Enzo Biochem, Inc. Is Fair to Shareholders - Business Wire
- 4 days ago - Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction - GlobeNewsWire
- 11 days ago - Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results - GlobeNewsWire
- 2 months ago - Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction - GlobeNewsWire
- 3 months ago - Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX - GlobeNewsWire
- 3 months ago - Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results - GlobeNewsWire
- 5 months ago - Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules - GlobeNewsWire